NeoTX Therapeutics Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.neotx.com
Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- NeoTX Therapeutics Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT04880863
- Locations
- 🇺🇸
NeoTX - 10312, El Paso, Texas, United States
🇺🇸NeoTX - 10310, Tyler, Texas, United States
🇺🇸NeoTX - 10308, Austin, Texas, United States
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- NeoTX Therapeutics Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03983954
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
🇮🇱Sheba Medical Center, Ramat Gan, Israel
© Copyright 2024. All Rights Reserved by MedPath